Cowen Prime Advisors’s GSK GSK Stock Holding History

Cowen Prime Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,600	Closed	-$80K	–	198
2018 Q3	$80K	Hold	1,600	–	–	0.04%	124
2018 Q2	$81K	Hold	1,600	–	–	0.04%	114
2018 Q1	$78K	Hold	1,600	–	–	0.04%	123
2017 Q4	$71K	Hold	1,600	–	–	0.03%	131
2017 Q3	$81K	Hold	1,600	–	–	0.04%	112
2017 Q2	$86K	Hold	1,600	–	–	0.04%	115
2017 Q1	$84K	Hold	1,600	–	–	0.04%	112
2016 Q4	$77K	Hold	1,600	–	–	0.04%	113
2016 Q3	$86K	Hold	1,600	–	–	0.04%	141
2016 Q2	$87K	Hold	1,600	–	–	0.04%	123
2016 Q1	$81K	Hold	1,600	–	–	0.04%	127
2015 Q4	$81K	Hold	1,600	–	–	0.04%	128
2015 Q3	$77K	Hold	1,600	–	–	0.04%	135
2015 Q2	$83K	Hold	1,600	–	–	0.03%	139
2015 Q1	$92K	Hold	1,600	–	–	0.04%	154
2014 Q4	$85K	Hold	1,600	–	–	0.03%	165
2014 Q3	$92K	Hold	1,600	–	–	0.04%	152
2014 Q2	$107K	Hold	1,600	–	–	0.04%	130
2014 Q1	$107K	Hold	1,600	–	–	0.04%	132
2013 Q4	$107K	Hold	1,600	–	–	0.04%	140
2013 Q3	$100K	Hold	1,600	–	–	0.04%	155
2013 Q2	$100K	Buy	+1,600	New	+$102K	0.04%	147

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

Cowen Prime Advisors's GSK Position: Q4 2018 in Review

Cowen Prime Advisors sold out of GSK (GSK) in Q4 2018, closing a stake of 1,600 shares — an estimated $80K sold.

Cowen Prime Advisors first reported a position in GSK in Q2 2013 and held it in 22 quarters. The position peaked at $107K in Q2 2014. 799 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

Cowen Prime Advisors reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
Cowen Prime Advisors sold 1,600 GSK shares in Q4 2018, an estimated $80K.
Cowen Prime Advisors first reported a position in GSK in Q2 2013 and held it in 22 quarters.
Cowen Prime Advisors's GSK position peaked at $107K in Q2 2014.
799 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on Cowen Prime Advisors's 13F filing for Q4 2018, filed 22 Jan 2019.